Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

18.03
-0.1700-0.93%
Post-market: 18.800.7700+4.27%18:13 EDT
Volume:1.79M
Turnover:32.42M
Market Cap:2.26B
PE:-11.29
High:18.72
Open:18.00
Low:17.68
Close:18.20
Loading ...

Apellis Pharmaceuticals Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
5 hours ago

BRIEF-Apellis Announces Craig Wheeler To Join The Board Of Directors

Reuters
·
Yesterday

RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating

MT Newswires Live
·
Yesterday

Apellis Announces Craig Wheeler to Join the Board of Directors

THOMSON REUTERS
·
Yesterday

Press Release: Apellis Announces Craig Wheeler to Join the Board of Directors

Dow Jones
·
Yesterday

Apellis Pharmaceuticals Inc : RBC Cuts Target Price to $21 From $24

THOMSON REUTERS
·
Yesterday

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating

MT Newswires Live
·
17 Apr

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

Zacks
·
15 Apr

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Apellis Pharmaceuticals Is Maintained at Sector Perform by Scotiabank

Dow Jones
·
03 Apr

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks
·
02 Apr

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

MT Newswires Live
·
01 Apr

Apellis Pharmaceuticals Inc - Pdufa Target Action Date for Empaveli Is July 28, 2025

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli® (Pegcetacoplan) for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire
·
01 Apr

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
24 Mar

U.S. RESEARCH ROUNDUP-American Electric Power, Block, Lenz Therapeutics

Reuters
·
18 Mar

Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $45 From $54

THOMSON REUTERS
·
18 Mar

Apellis Pharmaceuticals (APLS) Gets a Hold from Mizuho Securities

TIPRANKS
·
07 Mar